Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics

From: Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing

Patient Tumor Laterality Age at BC1 Histology Multicentric Size (mm) Lymph node metastasisa ER PR HER2b Ki67 NHG Treatment Time interval BC1 – BC2 (months) Metastasis after BC2c (months, location)
1 BC1 Left 61 Lobular No 32 No (0/4) Pos Pos UK UK 2 Tam 61 Yes (15, lung, liver, skeleton)
  BC2 Right   DCIS Yes 14 No (0/3) NA NA NA NA 3 None   
2 BC1 Left 41 Ductal No 15 No (0/10) Pos Pos UK UK 2 None 5 No (249)
  BC2 Right   Ductal No 14 No (0/5) Pos Pos 2+ 9 % 3 None   
3 BC1 Left 83 Ductal No 17 No (0/11) Neg Neg Neg 30 % 3 None 23 No (8)
  BC2 Right   Ductal No 25 No (0/12) Neg Neg Neg 75 % 3 None   
4 BC1 Left 51 Ductal No 25 Yes (9/21, PG) Neg Pos 3+ 14 % 3 RT, CT (7 CMF) 24 No (61)
  BC2 Right   Ductal No 25 Yes (7/28, PG) Pos Pos Neg 16 % 3 RT, Tam   
5 BC1 Left 43 Ductal No 10 No (0/23) Neg Neg Neg 80 % 3 RT, CT (9 CMF) 22 Yes (13, liver)
  BC2 Right   Ductal No 20 No (0/20) Neg Neg Neg 27 % 3 RT   
6 BC1 Right 51 Lobular Yes 70 Yes (3/8, PG) Pos Pos Neg 28 % 2 RT, CT (9 CMF) 17 Yes (5, brain)
  BC2 Left   Lobular Yes 12 Yes (23/26, PG) Pos Neg Neg 22 % 2 CT (3 Doxo–2 T)   
7 BC1 Right 52 Ductal No 16 No (0/11) Pos Pos Neg 21 % 3 RT, Tam 30 No (66)
  BC2 Left   Ductal No 16 No (0/1) Neg Neg Neg 40 % 3 CT (6 FEC)   
8 BC1 Left 46 Lobular No 80 Yes (33/34, PG) Pos Pos Neg 4 % 3 RT, CT (9 FEC) 11 Yes (16, lung)
  BC2 Right   Lobular Yes 55 Yes (11/25, PG) Pos Pos Neg 5 % 2 RT, Tam + oophorectomy   
9d BC1 Right 63 Ductal No 28 Yes (2/13) Pos Pos Neg UK 2 Tam–AI 0 Yes (62, skeleton)
  BC2 Left   Ductal No 55 Yes (1/12) Pos Pos Neg UK 3 RT, Tam–AI   
10 BC1 Right 32 Ductal No 23 No (0/1) Neg Neg UK UK 3 RT, CT (6 FEC) 35 Yes (13, skin)
  BC2 Left   Ductal No 45 Yes (12/12) Neg Neg Neg UK 2 RT   
  1. AI aromatase inhibitor, BC1 first breast cancer, BC2 second breast cancer, CMF cyclophosphamide, methotrexate and fluorouracil, CT chemotherapy (cycles and regime used in parentheses), DCIS ductal carcinoma in situ, Doxo doxorubicin, ER estrogen receptor, FEC fluorouracil, epirubicin, and cyclophosphamide, HER2 human epidermal growth factor receptor 2, NA not applicable, Neg negative, NHG Nottingham histological grade, PG periglandular growth, Pos positive, PR progesterone receptor, RT radiotherapy, T docetaxel, Tam tamoxifen, UK unknown
  2. aNumber of positive lymph nodes/number of investigated nodes in parentheses
  3. bHER2 determined with immunohistochemistry (Herceptest) where score 0–1 has been classified as negative. For score 2+ and 3+ the individual score is given in the table
  4. cIf the patient developed metastases, the time interval between BC2 and diagnosis of metastasis (months) and the site of the first metastasis is given within parentheses. In patients who do not develop metastases, the follow-up period (months) is given within parentheses
  5. dPatient 9 was diagnosed with her left and right breast cancer simultaneously (synchronous contralateral breast cancer), hence it cannot be said which tumor was first